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Introduction  
The regular therapy of schizophrenia includes a 
maintenance antipsychotic treatment, which improves 
the long-term prognosis of the disease and 
contributes to its transition into remission (Tandon, 
Physiology and 
Pharmacology 
Physiol Pharmacol 21 (2017) 25-33 www.phypha.ir/ppj 
Abstract 
Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic 
medications that are currently used in the treatment of patients with schizophrenia. 
Pharmacogenetic approaches offer the possibility of identifying patient-specific 
biomarkers for predicting the risk of this side effect. We investigated a possible 
relationship between variants (SNPs) in genes for cytochrome 2D6 (CYP2D6), 
dopamine-2 receptor (DRD2) and serotonin-2C receptor (HTR2C) and antipsychotic 
drug-induced hyperprolactinemia in patients with schizophrenia. 
 
Methods: Overall, 128 Russian patients with paranoid schizophrenia (61F/67M, aged 
18-65 y) were included. Serum prolactin concentration was measured with ELISA. 
DNA analysis and genotyping of CYP2D6 (rs3892097), DRD2 (rs6275) and HTR2C 
(rs6318) genes was done with StepOnePlus Real-Time PCR System using TaqMan® 
SNP Genotyping Assays (Applied Biosystems, USA). 
 
Results: Our study showed an association of the CYP2D6 (rs3892097) and HTR2C 
(rs6318) gene polymorphism with hyperprolactinemia in patients with schizophrenia 
on the background of therapy. No associations were identified between the DRD2 
(rs6275) gene polymorphism and the risk of antipsychotic-induced hyperprolactinemia 
in patients with schizophrenia. 
 
Conclusion: Our study confirms a contribution of genetic factors to the antipsychotic-
induced hyperprolactinemia in patients with schizophrenia. Further studies are 
required to unravel the genetic predictors of antipsychotic-induced side effects and to 
develop the personalized treatment strategies for patients with schizophrenia. 
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2011; Bruijnzeel et al., 2014). Patients with 
schizophrenia need to take this therapy for a long 
time, often throughout their entire lives (Miyamoto et 
al., 2005). Unfortunately, antipsychotics also have a 
wide spectrum of side effects, including metabolic, 
endocrine, cardiovascular and movement disorders 
(Staller, 2006; Lally and MacCabe, 2015). 
One of the common side effects of these drugs is 
hyperprolactinemia (Ajmal et al., 2014; Peuskens et 
al., 2014). Prolactin secretion is known to be under 
the permanent inhibitory control of dopamine. 
Therefore, the administration of antipsychotic drugs 
(which are potent dopamine receptor blockers) is a 
foreseeable, though certainly unwanted complication. 
Low efficacy of therapy along with intolerable side 
effects are the main causes of non-compliance and 
discontinuation of treatment in over 70% of patients 
with schizophrenia, often resulting in the relapse of 
psychosis (Miyamoto et al., 2005).  
Unravelling the genetic predictors of therapeutic 
response to antipsychotics or complications in the 
treatment of schizophrenia is expected to elucidate 
the biochemical pathways leading to antipsychotic-
induced side effects, and to offer possibilities for 
personalized treatment strategies of schizophrenic 
patients maximizing efficacy and minimizing the use 
of ineffective drugs. 
The genes of some members of the drug 
metabolizing cytochrome system (CYP2C19, 
CYP2D6 and CYP2C9), of proteins involved in 
serotonin (HTR2C, HTR2A, SLC6A4, etc.) and 
dopamine (DRD1, DRD3, etc.) neurotransmission are 
considered to be suitable candidates to predict 
unwanted features of the clinical effects of 
antipsychotics (Loonen and Ivanova, 2013; Müller et 
al., 2013). 
The present study aims to elucidate the role of three 
polymorphic variants of CYP2D6, DRD2 and HTR2C 
genes in the pathogenesis of antipsychotic-induced 
hyperprolactinemia in patients with schizophrenia. 
Materials and methods  
The study was carried out in accordance with The 
Code of Ethics of the World Medical Association 
(Declaration of Helsinki 1975, revised Fortaleza, 
Brazil, 2013) for experiments involving humans. A 
total of 128 ethnic Russian patients were studied, 
including 61 women and 67 men (mean age 34.9 ± 
1.2 years; from 18 to 65 years old) with a diagnosis of 
paranoid schizophrenia according to the diagnostic 
criteria of International Classification of Diseases-10. 
Patient inclusion in the study was carried out after 
obtaining a written consent of the patient to 
participate in the study. The information about drugs 
and study procedures was presented in a readily 
accessible form to each patient. None of the 
participants had a compromised capacity/ability to 
consent; hence, consent obtained from the next of kin 
was not necessary and not recommended by the 
Local Ethics Committee, which approved the study 
protocol. 
In- and out-patients were selected from departments 
of the clinic of biological therapy of mental patients of 
St. Petersburg’s V.M. Bekhterev Psychoneurological 
Research Institute. 
Methods used in this study include the assessment of 
clinical-therapeutic, clinical-endocrinologic (including 
anthropometric and laboratory variables) and 
statistical analysis. Patients were treated orally with 
atypical and/or classical antipsychotics in a flexible 
dosing regimen: risperidone, 33 persons (25.78% of 
examined patients); olanzapine, 28 (21.87%); 
quetiapine, 31 (24.21%) and classical antipsychotics, 
36 (28.14%). Antipsychotics were prescribed in 
average therapeutic doses as recommended by their 
package insert sheets. 
For objectification of the clinical condition the 
following scales were used: PANSS (Positive and 
Negative Syndrome Scale); CGI-S (Clinical Global 
Impressions of Severity); CGI-I (Clinical Global 
Impressions of Improvement) and UKU (Udvalg for 
Kliniske Undersøgelser) Side-Effect Rating Scale 
(Lingjaerde et al., 1987).  
The combined use of these scales covered the 
expected changes of the clinical condition during 
therapy. To identify and assess a possible 
neuroendocrine dysfunction the laboratory data                                               
were combined with the examination of the                               
patients’ anthropometric characteristics. Quantitative 
evaluation of the presence or absence of obesity, 
weight gain during treatment as well as the nature of 
the adipose tissue distribution (‘central’ or ‘hip‘ 
obesities) was performed using the study of body 
mass index, body weight and the waist 
circumference. 
Antipsychotic side effects were assessed with taking 
their main pathogenetic mechanisms into account, 
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including chance of development and degree. To 
carry out a differentiated assessment of the adverse 
events, the characteristic side effects of the studied 
antipsychotics were considered. These include 
neurological, psychiatric and somatic vegetative 
phenomena. In addition to these clinical events, the 
neuroendocrine dysfunction associated with 
pharmacotherapy was considered as well. 
The prolactin serum concentration was measured 
using Enzyme Linked Immunosorbent Assay kits 
(Roche Diagnostics). Assessing of the level of 
prolactin in the blood serum was carried out 
according to the normal ranges of this test: for men 
96-456 μIU/ml and for women 127-637 μIU/ml. 
Control of the blood glucose and lipid profile was 
carried out to identify the mechanisms of 
neuroendocrine disorders development. 
The control group for genetic studies included 93 
Table 1: The distribution of patients by the type of the course of schizophrenia 
Type of the course of schizophrenia 
Number of patients (n=128) 
Absolute (n) Relative (%) 
Episodic with progressive defect 105 82.03 
Episodic with stable defect 14 10.93 
Episodic remitting 9 7.04 
 
 
 Table 2: The severity of side effects on the UKU scale in the examined patients with schizophrenia (n=128) 
Parameter Scores 
Neurological side effects (the average score) 2.16±0.23 
Psychiatric side effects (the average score) 3.1±0.63 
Other side effects 
Rash 0.0 
Itch 0.0 
Photosensitivity 0.0 
Increased pigmentation 0.0 
Weight gain 1.58±0.39 
Weight loss 0.0 
Menorrhagia 0.0 
Amenorrhea 2.93±0.23 
Galactorrhea 2.23±0.19 
Gynecomastia 1.02±0.34 
Increased libido 0.0 
The weakening of libido 2.32±0.68 
Erectile dysfunction 2.09±0.23 
Ejaculation dysfunction 1.98±0.09 
Orgasmic dysfunction 1.96±0.33 
Vaginal dryness 0.0 
Headache 1.07±0.45 
Physical addiction 0.0 
Psychic addiction 0.0 
Average score 2.16±1.6 
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mentally and physically healthy ethnically Russian 
individuals (63 women and 30 men, aged 17-65 years 
old).  
DNA extraction was conducted according to standard 
protocols. Genotyping of CYP2D6 (rs3892097), 
DRD2 (rs6275) and HTR2C (rs6318) genes was 
done with StepOnePlus Real-Time PCR System 
using TaqMan® SNP Genotyping Assays (Applied 
Biosystems, USA) in the Laboratory of Molecular 
Genetics and Biochemistry at the Mental Health 
Research Institute (Tomsk).  
Statistical analysis was performed using the SPSS 
20.0 program. The Hardy–Weinberg equilibrium 
(HWE) and differences in genotype frequencies were 
tested using a chi-square test. As the HTR2C gene is 
X-bound, HWE was not calculated. Differences were 
considered significant at P<0.05. The associations of 
different genotypes with the development of the 
disease were evaluated by the value of the odds ratio 
(OR). 
Results 
Patient characteristics 
The mean PANSS total score in examined patients 
was 86.32 ± 5.03 points (ranged from 70 to 120 
points). The average duration of disease was 2.82 ± 
0.93 years. The average duration of actual 
exacerbation was 8.39 ± 4.03 weeks. The average 
number of previous exacerbations was 2.48 ± 1.72. 
The distribution of patients by leading clinical 
syndrome was as follows: 97 patients (75.78%) had 
the leading hallucinatory-paranoid syndrome and 31 
(21.22%) patients - clinical paranoid syndrome. The 
distribution of patients by type of the disease is 
presented in Table 1. Patients with episodic course of 
the disease with a gradual increase in the severity of 
the defect predominated. 
According to the study design, the evaluation of the 
incidence and severity of side effects when used 
antipsychotics was performed using anthropometric 
surveys and collecting the peripheral blood of 
patients to determine series of biochemical and 
hormonal parameters. To assess the severity of side 
effects occurring in patients the data of UKU Side-
Effect Rating Scale were analyzed (Table 2). 
 
Prolactin-related side effects  
Evaluation of side effects of neuroendocrine 
spectrum was carried out with the help of the relevant 
paragraphs of the scale UKU, united under the 
heading "other side effects", which also contains 
indicators of toxic-allergic genesis. As shown in Table 
2, the structure of the clinical syndrome of 
hyperprolactinemia in women on acute treatment with 
all medications was characterized by menstrual 
irregularities, galactorrhea, decreased libido, 
engorgement and tenderness of breast. In men, the 
clinical syndrome structure included decreased libido, 
disturbances of erectile, ejaculatory function, 
Table 3: The metabolic profile of the examined patients with schizophrenia 
Index Level 
Body mass index (kg / m
2
) 29.02±2.14 
Waist circumference (cm) 89.03±5.19 
Hip circumference (cm)  113.92±10.64 
Glucose (mmol/ L) 5.46±0.97 
Cholesterol (mmol/L) 7.19±1.29 
Triglycerides (mmol/ L) 2.17±0.46 
High-density lipoproteins 1.09±0.32 
Low-density lipoproteins 3.82±1.02 
Blood pressure (systolic, diastolic) (mm Hg) 121±10; 82±8 
Prolactin (μIU/ml)                                                     
Men 
women 
 
1983±129 
2189±312 
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gynecomastia and galactorrhea. The metabolic profile 
of patients is presented in Table 3. 
Based on the data obtained, all patients with 
schizophrenia were divided into two groups: those 
with hyperprolactinemia (serum prolactin is more than 
2000 μIU/ml) and without hyperprolactinemia (serum 
prolactin is less than 2000 μIU/ml). Genotyping of 
DNA samples was carried out in these groups of 
Fig.2. Comparison of genotype frequencies of DRD2 (rs6275) gene polymorphism in patients with schizophrenia and 
healthy persons. * P<0.05 compared to the healthy persons. 
 
Fig.1. Comparison of genotype frequencies of CYP2D6 (rs3892097) gene polymorphism in schizophrenic patients with and 
without hyperprolactinemia (HPRL). * P<0.05 compared to the schizophrenic patients without hyperprolactinemia. 
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patients and in the group of healthy individuals. 
 
Hyperprolactinemia and genotypes 
The analysis of the prevalence of CYP2D6 
(rs3892097) and DRD2 (rs6275) genotypes in 
patients and control sample did not reveal deviance 
from Hardy–Weinberg equilibrium.  
Genotyping of the control group for the CYP2D6 
(rs3892097) marker showed a high frequency of 
homozygous GG genotype (75.2%), and then in 
descending order go genotypes AG (23.6%) and AA 
(1.2%). The major G and a minor A alleles were 
represented in the control group, with frequencies of 
92.6% and 7.4%, respectively.  
The prevalence of genotypes of the HTR2C (rs6318) 
gene polymorphic variant in the control group was as 
the following: GG, 84.9%; GC, 10.8%; CC, 4.3%. 
Alleles were presented by the following frequencies: 
G, 92% and C, 8%. In the control group for the DRD2 
(rs6275) gene the following prevalence of the 
genotypes was identified: CC, 39.8%; CT, 45.2%; TT, 
15%. The major C and a minor T were presented in 
the control group with frequencies of 65.9% and 
34.1%, respectively. 
A comparison of the genotype frequencies between 
patients and healthy individuals revealed no 
differences for the CYP2D6 (rs3892097) 
polymorphism, leading to the conclusion about the 
absence of the association of this gene with the 
development of schizophrenia (χ2 = 2.1, P>0.05). 
However, a comparison of the genotype frequencies 
between patients with hyperprolactinemia and the 
group with normal level of prolactin revealed 
differences for the CYP2D6 (rs3892097) gene 
polymorphism, thus providing the evidence for the 
association of this gene variant with the development 
of hyperprolactinemia in patients with schizophrenia 
on the background of antipsychotic therapy (χ2 = 7.2, 
P<0.005; Fig. 1). Also, it can be speculated that the 
TT genotype has a protective effect regarding 
antipsychotic-induced hyperprolactinaemia in 
schizophrenic patients (OR = 0.75; 95% CI: 0.634-
0.887; P = 0.0008).  
Comparison of the groups of patients and healthy 
individuals showed an association of DRD2 (rs6275) 
gene polymorphism with schizophrenia (χ2 = 7.85, 
Fig.3. Comparison of genotype frequencies of HTR2C (rs6318) gene polymorphism in women schizophrenic patients with 
and without hyperprolactinemia (HPRL). *P<0.05 compared to the women schizophrenic patients without 
hyperprolactinemia. 
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P<0.005). In the group of patients with schizophrenia, 
the GG genotype of the DRD2 gene is the most 
common followed by AG and AA genotypes (Fig. 2). 
In the control group, in contrast, AG is the most 
common genotype.  
The prevalence of genotypes in patients with and 
without hyperprolactinemia for allelic variants of 
DRD2 (rs6275) gene does not differ. Thus, according 
to our study, rs6275 is not associated with the 
development of hyperprolactinemia in schizophrenic 
patients on the background of antipsychotic therapy 
(χ2 = 0.467, P = 0.49).  
Due to the fact that serotonin receptor gene HTR2C 
is localized on X-chromosome, the prevalence of 
genotypes and alleles of polymorphic variant rs6318 
was analyzed separately in women and men. We did 
not find any statistically significant differences for 
rs6318 of HTR2C gene between patients with 
schizophrenia and healthy individuals separated by 
gender. Thus, according to our data, the polymorphic 
variant rs6318 is not associated with the development 
of schizophrenia (χ2 = 7.2, P>0.05).  
When comparing men and women with 
schizophrenia, with and without hyperprolactinemia 
we revealed an association of HTR2C (rs6318) gene 
polymorphism with the development of 
hyperprolactinemia in women schizophrenic patients, 
on the background of antipsychotic therapy (χ2 = 8.3; 
P<0.005) (Fig. 3). 
Allele C has a protective effect with respect to 
hyperprolactinemia development (OR = 0.930; CI = 
0.306-2.828; P = 0.89798), and allele G is a 
predisposing allele (OR = 1.075; CI = 0.354-3.271; P 
= 0.89798), but these data do not reach the level of 
statistical significance. 
Discussion 
Our study provided the evidence for the association 
of the CYP2D6 (rs3892097) gene polymorphism with 
the development of hyperprolactinemia in patients 
with schizophrenia as a respond to the antipsychotic 
therapy. Also, it can be concluded that the TT 
genotype has a protective effect regarding 
antipsychotic-induced hyperprolactinemia in 
schizophrenic patients. Homozygosity for null alleles 
and heterozygosity for low activity alleles is seen in 
most clinically important phenotype of poor 
metabolizer lacking the enzymatic activity of 
CYP2D6. Ultrarapid metabolizers carry three or more 
normal copies of the gene in their genotype (Steen et 
al., 1995), although ultrarapid metabolizers without 
duplication are described. The poor metabolizer 
phenotype for CYP2D6 is associated with adverse 
effects of psychotropic drugs. In this study, we did not 
determine the metabolic phenotypes; however, the 
analyzed SNP rs3892097 is known to lead to an 
inactive form of the enzyme and therefore results in 
reduction of CYP2D6 function (Van der Merwe et al., 
2012). 
According to our study, the GG genotype of the 
DRD2 (rs6275) gene polymorphism is the most 
common followed by AG and AA genotypes in the 
group of patients with schizophrenia. It is possible to 
make an assumption that the GG genotype 
predisposes to schizophrenia, since its frequency in 
patients is higher in comparison to the control group. 
Also we have shown that DRD2 (rs6275) gene 
polymorphism is not associated with the development 
of hyperprolactinemia in schizophrenic patients on 
the background of antipsychotic therapy.  It is worth 
noting the controversial data in the literature                       
about the associations of DRD2 gene with                               
the hyperprolactinemia development. Perhaps a                     
series of genetic and pharmacokinetic factors is                        
behind the phenomenon of antipsychotic-induced 
hyperprolactinemia. 
According to our data, the polymorphic variant 
HTR2C (rs6318) is not associated with the 
development of schizophrenia. At the same time, the 
serotonergic system is considered to be one of the 
most important neurotransmitter systems contributing 
to the pathogenesis of schizophrenia or at least 
determining an important part of the response to 
antipsychotic drugs. A number of hypotheses of the 
pathogenesis of schizophrenia is associated with the 
assumption of impairment of specific links of 
metabolism, in particular of the biogenic amines. For 
example, the indolamine hypothesis postulates 
involvement of serotonin and its metabolites, as well 
as other indole derivatives in the mechanisms of 
mental activity, an impairment of which may lead 
mental disorders, in particular to the development of 
schizophrenic symptoms (Nothern et al., 1995). 
HTR2C (rs6318) gene polymorphism results in the 
Cys23Ser amino acid substitution associated with the 
dysfunction of the serotonin neurotransmission in 
various psychiatric disorders and the development of 
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side effects of antipsychotic and antidepressant 
therapy (Drago and Serretti, 2009). The Ser23 allele 
is associated with weight gain in women with 
schizophrenia receiving therapy with atypical 
antipsychotics (Houston et al., 2012). With respect to 
motor side effects of antipsychotic therapy it has 
been shown the protective value of the Ser23 allele in 
the development of tardive dyskinesia (Al Hadithy et 
al., 2009). The HTR2C is an excitatory G-protein 
coupled receptor which has been described to have 
constituitive activity in the absence of 
neurotransmitter (Aloyo et al., 2009). This means, 
that a complete blockade of the receptor results in a 
decrease of the excitatory activity of the receptor and 
therefore also a decrease of the activation of the cell 
carrying these receptors. The presence of less active 
HTR2C on prolactin producing cells of the pituitary 
gland in C-allele carriers could result in a decrease of 
prolactin secretion due to under stimulation of these 
cells.  
Conclusion 
Thus, our study identified an association of CYP2D6 
(rs3892097) and HTR2C (rs6318) gene 
polymorphisms with antipsychotic induced 
hyperprolactinemia in patients with schizophrenia. 
We demonstrated that hyperprolactinemia in our 
patient population is related to gynecological 
disturbances in women and sexual disorders in men. 
Further search for genetic markers associated with 
the development of side effects of antipsychotic 
treatment will allow developing effective methods for 
diagnosis and treatment of schizophrenia and will 
contribute to compliance of patients with mental 
health problems to the psychotropic therapy for 
improvement of their physical condition and quality of 
life. 
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